T-BET drives the conversion of human type 3 innate lymphoid cells into functional NK cells.
EOMES
ILC3
NK cells
T-BET
human innate lymphoid cells
plasticity
transdifferentiation
Journal
Frontiers in immunology
ISSN: 1664-3224
Titre abrégé: Front Immunol
Pays: Switzerland
ID NLM: 101560960
Informations de publication
Date de publication:
2022
2022
Historique:
received:
22
06
2022
accepted:
30
09
2022
entrez:
4
11
2022
pubmed:
5
11
2022
medline:
8
11
2022
Statut:
epublish
Résumé
Type 3 innate lymphoid cells (ILC3s) are characterized by RORγt expression and they produce IL-22 upon activation. ILC3s play a role in maintenance of barrier integrity in the intestine. Under inflammatory conditions, the ILC composition of the mucosal tissues is altered due to a high degree of plasticity. It has been extensively demonstrated that both murine and human ILC3s convert into ILC1s to mediate appropriate immune responses. However, plasticity between human ILC3s and NK cells is less well documented. As T-BET and EOMES are key transcription factors in NK cell differentiation, we investigated whether ectopic T-BET or EOMES expression converts human ILC3s into NK cells. ILC3s with ectopic T-BET and EOMES expression downregulate RORγt expression, while T-BET-overexpressing ILC3s additionally upregulate EOMES expression. High E ctopic T-BET expression in ILC3s results in transdifferentiation towards CD94
Identifiants
pubmed: 36330517
doi: 10.3389/fimmu.2022.975778
pmc: PMC9623292
doi:
Substances chimiques
Nuclear Receptor Subfamily 1, Group F, Member 3
0
Perforin
126465-35-8
Transcription Factors
0
T-box transcription factor TBX21
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
975778Informations de copyright
Copyright © 2022 Kiekens, Wahlen, Persyn, De Vos, Taghon, Vandekerckhove and Leclercq.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Front Immunol. 2019 Sep 11;10:2180
pubmed: 31572388
Eur J Immunol. 2021 Apr;51(4):811-823
pubmed: 33300130
Methods Mol Biol. 2010;612:15-26
pubmed: 20033631
Nat Immunol. 2019 Aug;20(8):980-991
pubmed: 31209406
Semin Immunopathol. 2018 Jul;40(4):407-419
pubmed: 29948108
Front Immunol. 2021 Sep 24;12:732511
pubmed: 34630413
J Immunol. 2001 Oct 15;167(8):4468-75
pubmed: 11591773
Cell Rep. 2014 Jul 10;8(1):150-62
pubmed: 24953655
Immunity. 2016 May 17;44(5):1140-50
pubmed: 27178467
Nat Rev Immunol. 2013 Nov;13(11):777-89
pubmed: 24113868
Immunity. 2015 Jul 21;43(1):146-60
pubmed: 26187413
Immunity. 2010 Nov 24;33(5):736-51
pubmed: 21093318
Biochem Biophys Res Commun. 1997 Aug 28;237(3):752-7
pubmed: 9299439
Nat Rev Immunol. 2020 Sep;20(9):552-565
pubmed: 32107466
Nat Immunol. 2013 Mar;14(3):221-9
pubmed: 23334791
Cell Rep. 2016 Jul 12;16(2):379-391
pubmed: 27373165
Nat Commun. 2021 Sep 14;12(1):5446
pubmed: 34521844
Nat Rev Immunol. 2013 Feb;13(2):145-9
pubmed: 23348417
Cell. 2018 Aug 23;174(5):1054-1066
pubmed: 30142344
JCI Insight. 2017 Mar 9;2(5):e90063
pubmed: 28289707
Nat Immunol. 2016 Jun 21;17(7):765-74
pubmed: 27328006
Nat Immunol. 2016 Jun;17(6):626-35
pubmed: 27111143
Immunity. 2018 Jun 19;48(6):1104-1117
pubmed: 29924976
Immunity. 2014 Sep 18;41(3):354-365
pubmed: 25238093
Front Immunol. 2014 May 14;5:217
pubmed: 24860576
Nat Immunol. 2013 Apr;14(4):389-95
pubmed: 23455676
J Exp Med. 2018 May 7;215(5):1383-1396
pubmed: 29511064
Blood Adv. 2017 Dec 14;1(27):2679-2691
pubmed: 29296921
Nature. 2013 Feb 14;494(7436):261-5
pubmed: 23334414
Nat Immunol. 2017 Sep;18(9):995-1003
pubmed: 28759002
Nat Immunol. 2016 Jun 21;17(7):758-64
pubmed: 27328005
Immunity. 2012 Jan 27;36(1):55-67
pubmed: 22261438
Nat Immunol. 2017 Sep;18(9):1004-1015
pubmed: 28759001
Eur J Immunol. 2012 Aug;42(8):1916-23
pubmed: 22865043
Nat Immunol. 2016 Jun;17(6):636-45
pubmed: 27111145
Curr Opin Immunol. 2017 Feb;44:61-68
pubmed: 28359987